Companies › Theradex
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jul 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 2 | Leukemia, Myelomonocytic, Chronic | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07033598 | Pacritinib | Phase 2 | Leukemia, Myelomonocytic, Chronic | Oncology | Jul 2028 |
Swedish Orphan Biovitrum Bristol-Myers Squibb AbbVie GSK Daiichi Sankyo Chia Tai Tianqing Pharmaceutical Group Sun Pharmaceutical Industries Alfasigma Takeda Incyte
NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.